Methods and compositions for tissue regeneration

• US 7,449,333 B2
• Filed: 09/05/2003
• Issued: 11/11/2008
• Est. Priority Date: 09/01/2000
• Status: Expired due to Fees

• Current Assignee: Smith & Nephew Incorporated (Smith & Nephew PLC)
• Original Assignee: DFB Pharmaceuticals, Inc.
• Inventors: Rinsch, Christopher, Hunziker, Thomas, Mis, Beatrice, Rolland, Eric
• Primary Examiner(s): Romeo; David
• Assistant Examiner(s): Gamett; Daniel C
• Application Number:
  US10/526,853
• Publication Number:
  US 20060121002A1
• Time in Patent Office: 1,894 Days
• Field of Search: None
• US Class Current: 435/325
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/33 Fibroblasts
• CPC Class Codes: A61K 35/36 Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells islets of Langerhans A61K35/39
• CPC Class Codes: A61K 38/18 Growth factors; Growth regulators
• CPC Class Codes: A61K 38/19 Cytokines; Lymphokines; Interferons
• CPC Class Codes: A61K 38/363 Fibrinogen
• CPC Class Codes: A61K 38/4833 Thrombin (3.4.21.5)
• CPC Class Codes: A61K 41/0023 Agression treatment or altering
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/10 Dispersions; Emulsions A61K9/06 takes precedence; composition of dispersions, emulsions A61K47/00
• CPC Class Codes: A61K 9/19 lyophilised , i.e. freeze-dried, solutions or dispersions lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00
• CPC Class Codes: A61K 9/7015 Drug-containing film-forming compositions, e.g. spray-on
• CPC Class Codes: A61L 15/40 containing ingredients of undetermined constitution or reaction products thereof , e.g. plant or animal extracts
• CPC Class Codes: A61L 26/0057 Ingredients of undetermined constitution or reaction products thereof
• CPC Class Codes: A61L 27/3616 Blood, e.g. platelet-rich plasma
• CPC Class Codes: A61L 27/3633 Extracellular matrix [ECM]
• CPC Class Codes: A61L 27/3804 characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
• CPC Class Codes: A61L 27/3813 Epithelial cells, e.g. keratinocytes, urothelial cells
• CPC Class Codes: A61L 27/3886 : comprising two or more cell types
• CPC Class Codes: A61P 17/02 : for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 19/04 : for non-specific disorders of the connective tissue
• CPC Class Codes: C12N 2502/094 : keratinocytes
• CPC Class Codes: C12N 2502/1323 : Adult fibroblasts
• CPC Class Codes: C12N 2510/00 : Genetically modified cells
• CPC Class Codes: C12N 2510/04 : Immortalised cells
• CPC Class Codes: C12N 5/0656 : Adult fibroblasts
• CPC Class Codes: C12N 5/0698 : Skin equivalents

Abstract

The present invention provides the use and composition of matter of angiogenic or other growth/cytokine factors expressed by mixtures of allogeneic human cell strains or lines of various types and stages of differentiation. Also provided are unencapsulated preparations (mixed with or applied to extracellular matrix material or synthetic biocompatible substances) for the purpose of temporary application to wounds or defects in the skin or other tissues for the restoration of blood supplying connective tissue to enable organ-specific cells to reestablish organ integrity as well as to inhibit excessive scar formation.

Claims

1. A cell preparation for tissue regeneration comprising

a) a first component comprising an extracellular matrix or matrix material containing fibrinogen;

and

b) a second component comprising from about 1 ×

10³ cells/μ

l to about 50 ×

10³ cells/μ

l and thrombin, wherein the cells comprise one or more keratinocytes and fibroblasts that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGFβ

, angiopoietin, EGF, IL-Iβ

, IL-6, IL-8, TGFα

, and TNFα

,

wherein the one or more keratinocytes and fibroblasts are mitotically inactivated allogeneic cells.

2. The cell preparation of claim 1, wherein the one or more keratinocytes and fibroblasts are differentiated fibroblasts and keratinocytes.

3. The cell preparation of claim 1, wherein the cell preparation is in the form of a paste.

4. The cell preparation of claim 1, wherein the cell preparation is in the form of a spray.

5. The cell preparation of claim 1, wherein the one or more keratinocytes and fibroblasts are mitotically inactivated by administration of mitomycin C or other chemically-based mitotic inhibitors, irradiation with γ

-Rays, irradiation with X-Rays, or irradiation with UV light.

6. The cell preparation of claim 1, wherein the one or more keratinocytes and fibroblasts are immortalized using at least one gene/polypeptide selected from the group consisting of the 12S and 13S products of the adenovirus E1A genes, hTERT, SV40 small T antigen, SV40 large T antigen, papilloma viruses E6 and E7, the Epstein-Barr Virus (EBV), Epstein-Barr nuclear antigen-2 (EBNA2), human T-cell leukemia virus-1 (HTLV-1), HTLV-1 tax, Herpesvirus saimiri (HVS), mutant p53, myc, c-jun, c-ras, c-Ha-ras, h-ras, v-src, c-fgr, myb, c-myc, 5 n-myc, and Mdm2.

7. The cell preparation of claim 1, wherein the one or more keratinocytes and fibroblasts naturally secretes the one or more biologically active molecules.

8. The cell preparation of claim 1, wherein the extracellular matrix or matrix material further comprises a collagen, alginate, alginate beads, agarose, fibrin, fibrin glue, blood plasma, fibrin beads, laminin, proteoglycan, fibronectin, chitosan, or heparin.

9. The cell preparation of claim 1, wherein the second component further comprises a cryoprotectant.

10. The cell preparation of claim 9, wherein the cryoprotectant is selected from the group consisting of a 10% by volume of a glycerol solution, a 15% by volume of a glycerol solution, and a 15% glycerol and 5% human serum albumin by volume of a solution.

11. The cell preparation of claim 10, wherein the cryoprotectant is glycerol.

12. A kit comprising, in one or more containers, the cell preparation of claim 1.

13. The kit of claim 12, wherein the first component and the second component are cryopreserved prior to shipping and subsequently thawed prior to use.

14. The kit of claim 13, wherein the first and second components are each contained in a separate vial having a removable screw cap, wherein the vial is sterile and is made of a material resistant to low temperatures and wherein the removable lid can be replaced with a spray pump following thawing of the first and second components prior to use.

15. The kit of claim 14, wherein the spray pump delivers a volume of approximately 130 μ

l per spray.

16. The kit of claim 14, wherein the material resistant to low temperatures is selected from the group consisting of glass, polypropylene, polyethylene, and ethylene vinyl acetate (EVA).

17. The kit of claim 14, wherein the vials are sealed within a pouch or container prior to cryopreservation, wherein the pouch or container is fabricated of a material capable of withstanding temperatures ranging from −

800°

C. to −

196°

C. and wherein the pouch or container protects the first and second components from contamination during cryopreservation and subsequent thawing.

18. The kit of claim 17, wherein the pouch or container is waterproof.

19. A method of using the kit of claim 12, the method comprising administering the first and second components to a wound site on a patient in need of treatment wherein the combination of the first and second components forms a cell preparation suitable for tissue regeneration.

20. The method of claim 19, wherein the cell preparation is in the form of a paste.

21. The method of claim 19, wherein the cell preparation is in the form of a spray.

22. The method of claim 19, wherein the second component optionally further comprises a cryoprotectant.

23. The method of claim 22, wherein the cryoprotectant is selected from the group consisting of a 10% by volume of a glycerol solution, a 15% by volume of a glycerol solution, and a 15% glycerol and 5% human serum albumin by volume of a solution.

24. The method of claim 19, wherein the first and second components are topically administered to the wound site on the patient.

25. The method of claim 19, wherein the first and second components are sprayed onto the wound site on the patient.

26. The method of claim 25, wherein the first and second components are combined on the wound site.

27. The method of claim 25, wherein the first and second components are combined before reaching the wound site.

28. A method of administering cell preparation of claim 1 to a wound site on a patient in need of treatment, the method comprising a) providing the first component;

b) providing the second component;

c) combining the first and second components to form the cell preparation; and

d) administering the cell preparation to the wound site.

29. The method of claim 28, wherein the cell preparation is topically applied to the wound site.

30. The method of claim 28, wherein the cell preparation is in the form of a paste.

31. The method of claim 28, wherein the cell preparation is in the form of a spray.

32. The method of claim 28, wherein the second component optionally further comprises a cryoprotectant.

33. The method of claim 32, wherein the cryoprotectant is selected from the group consisting of a 10% by volume of a glycerol solution, a 15% by volume of a glycerol solution, and a 15% glycerol and 5% human serum albumin by volume of a solution.

34. The method of claim 28, wherein the first and second components are sprayed on the wound site.